Bentley received approval to market a 30mg generic version of depression drug Celexa (citalopram) in Spain through its wholly-owned subsidiaries, Laboratorios Rimafar and Laboratorios Davur, and a branded-generic
The company has presented data from a study involving 17 patients with advanced solid tumors. Most patients in the study were heavily pre-treated: the median number of prior
Exendin-4 is a glucagon-like peptide-1 (GLP-1) homolog and an agonist for the GLP-1 receptor. It lowers blood glucose levels through a distinct mechanism complementary to the mechanisms of
The trial is the second of two overlapping, multi-national trials in the phase III alfimeprase program for catheter occlusion. The trial will evaluate the safety and efficacy of
In a report, the Canadian Program on Genomics and Global Health (CPGGH), part of the University of Toronto’s Joint Centre for Bioethics (JCB), calls for a global network
The study, published in the journal Cancer, reveals that combination therapy showed the greatest benefit for HIV patients suffering from aggressive malignant non-Hodgkin’s lymphoma. This benefit was most
The National Institute on Drug Abuse estimates that nearly half a million eighth- and 10th-grade students abuse anabolic-androgenic steroids (AASs) each year. Not only can steroids set kids
Androgen deprivation therapy, also known as hormone therapy, is the gold standard of care for men whose prostate cancer is advanced and has spread throughout the body. The
The researchers, at Johannes Gotenberg University, simultaneously investigated the serum activities of DR-70 and the standard test, CA-125, in 61 preoperative patients with histologically confirmed ovarian carcinoma, and
Novartis said that it is confident that providing the requested additional information to the FDA will help obtain final approval by the end of 2006. Aclasta has already
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.